References
1. European Centre for Disease Prevention and Control. Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. May 11, 2021. https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emerge
2. Interim guidelines on the management of care for patients with COVID-19 infection. Order of the Ministry of Health of the Republic of Belarus No. 1195 dated 11.11.2020. (in Russian)
3. Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Akopyan Z.A., et al. Proactive antiinflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in Open prospective RandomIzed Trial (COLORIT). Kardiologiia. 2020; 60 (9): 4–21. DOI: https://doi.org/10.18087/cardio.2020.9.n1338 (in Russian)
4. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844–7. DOI: https://doi.org/10.1111/jth.14768
5. Thachil J., Tang N., Gando S., Falanga A., et al. STH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18 (5): 1023–6. DOI: https://doi.org/10.1111/jth.14810
6. Wichmann D., Sperhake J.-P., Lütgehetmann M., Steurer S., et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020; 173 (4): 268–77. DOI: https://doi.org/10.7326/M20-2003
7. Paranjpe I., Fuster V., Lala A., Russak A.J., et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020; 76 (1): 122–4. DOI: https://doi.org/10.1016/j.jacc.2020.05.001
8. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191: 145–7. DOI: https://doi.org/10.1016/j.thromres.2020.04.013
9. Llitjos J., Leclerc M., Chochois C., Monsallier J., et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020; 18 (7): 1743–6. DOI: https://doi.org/10.1111/jth.14869
10. Wise J. Covid-19 and thrombosis: what do we know about the risks and treatment. BMJ. 2020; 369: 2058. DOI: https://doi.org/10.1136/bmj.m2058
11. Wang T., Chen R., Liu C., Liang W., et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020; 7 (5): 362–3. DOI: https://doi.org/10.1016/S2352-3026(20)30109-5
12. Darmon P., Dadoun F., Boullu-Ciocca S., Grino M., et al. Insulin resistance induced by hydrocortisone is increased in pacients with abdominal obesity. Am J Physiol Endocrinol Metab. 2006; 291 (5): E995–1002. DOI: https://doi.org/10.1152/ajpendo.00654.2005
13. Zarković M., Beleslin B., Ćirić J., Penezić Z., et al. Glucocorticoid effect on insulin sensitivity: a time frame. J Endocrinol Invest. 2008; 31 (3): 238–42. DOI: https://doi.org/10.1007/BF03345596
14. Shono A., Mori S., Nakamura K., Yatomi A., et al. Glucocorticoid-sensitive paroxysmal atrial fibrillation, sick sinus syndrome, and mitral regurgitation in a patient with malignant rheumatoid vasculitis. Intern Med. 2019; 58 (21): 3093–8. DOI: https://doi.org/10.2169/internalmedicine.3090-19
15. Li H., Chen C., Hu F., Wang J., et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS CoV, or MERS-CoV infection: a systematic review and meta-anal ysis. Leukemia. 2020; 34 (6): 1503–11. DOI: https://doi.org/10.1038/s41375-020 0848-3
16. Zha L., Li S., Pan L., Tefsen B., et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020; 212 (9): 416–20. DOI: https://doi.org/10.5694/mja2.50577
17. Zhao Z. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003; 52 (Pt 8): 715–20. DOI: https://doi.org/10.1099/jmm.0.05320-0
18. Ho J.C., Ooi G.C., Mok T.Y., Chan J.W., et al. High dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003; 168 (12): 1449–56. DOI: https://doi.org/10.1164/rccm.200306-766OC
19. Majoor C.J., Sneeboer M.M.S., de Kievit A., Meijers J.C.M., et al. The influence of corticosteroids on hemostasis in healthy subjects. J Thromb Haemost. 2016; 14 (4): 716–23. DOI: https://doi.org/10.1111/jth.13265
20. Johannesdottir S.A., Horváth-Puhó E., Dekkers O.M., Cannegieter S.C., et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case control study. JAMA Internal Medicine. 2013; 173 (9): 743. DOI: https://doi.org/10.1001/jamainternmed.2013.122
21. Stuijver D.J.F., Majoor C.J., van Zaane B., Souverein P.C., et al. Use of oral glucocorticoids and the risk of pulmonary embolism. Chest. 2013; 143 (5): 1337–42. DOI: https://doi.org/10.1378/chest.12-1446
22. The RECOVERY Collaborative Group, Horby P., Lim W.S., Emberson J.R., Mafham M., et al. dexamethasone in hospitalized patients with Covid-19 – preliminary report. N Engl J Med. 2021; 384 (8): 693–704. DOI: https://doi.org/10.1056/NEJMoa2021436.
23. Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.Т., et al. Steroid pulse-therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study). Kardiologiya [Kardiologiia]. 2020; 60 (6): 15–29. DOI: https://doi.org/10/18087/cardio.2020.6.n1226 (in Russian)
24. Salivonchik D., Stoma I., Dotsenko E., Ivantsov O., et al. Efficacy and safety of preventive anticoagulation in patients with COVID-19-pneumonia. Kardiologiya v Belarusi [Cardiology in Belarus]. 2021; 13 (3): 336–53. (in Russian)
25. Salivonchik D.P. COVID-19: step-by-step treatment strategies. Problemy zdorov’ya i ekologii [Health and Ecology Issues]. 2021; (2): 155–62. DOI: https://doi.org/10.51523/2708-6011.2021-18-2-22 (in Russian)
26. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324 (13): 1330–41. DOI: https://doi.org/10.1001/jama.2020.17023; PMID: 32876694.
27. Task Force Members, Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34 (38): 2949–3003. DOI: https://doi.org/10.1093/eurheartj/eht296. Erratum in: Eur Heart J. 2014; 35 (33): 2260–1. PMID: 23996286.
28. Salivonchyk D., Salivonchyk E. Energy collapse in COVID-19: Diagnostics and treatment. Recipe. 2020; (5): 680–693. DOI: https://doi.org/10.34883/PI.2020.23.5.004 (in Russian)
29. Salivonchyk D., Salivonchyk E. Energy covid-19 collapse: new diagnostic markers, treatment aspects. Zhurnal kardiorespiratornykh issledovaniy [Journal of Cardiorespiratory Research]. 2021; 2 (2): 68–76. (in Russian)
30. Mazur I.A. Thiotriazoline. Zaporozhye. 2005: 146 p. (in Russian)